William Michael Rosellini
Founder bei Cytoimmune Therapeutics, Inc.
Profil
William Michael Rosellini is the founder of Nuviant Medical, Inc. (2014), MicroTransponder, Inc. (2006), Rosellini Scientific LLC (2005), and Cytoimmune Therapeutics, Inc. (2019).
He held the titles of Chief Executive Officer & Director at Nuviant Medical, Inc., Chairman & Chief Executive Officer at MicroTransponder, Inc., and Chairman at Rosellini Scientific LLC.
Currently, he is the President & Head-Media Enquiries at Cytoimmune Therapeutics, Inc. Mr. Rosellini's former jobs include President, Chief Executive Officer & Director at Nexeon MedSystems, Inc. (2015-2020), Chief Executive Officer at Lexington Technology Group, Inc. (2012-2013), Chief Executive Officer at Sarif Biomedical LLC (2013-2014), Independent Director at Marathon Digital Holdings, Inc. (2013-2016), and Commercialization Director at The University of Texas at Dallas (2013-2015).
Mr. Rosellini's education history includes graduate degrees from the University of Southern California and Rutgers State University of New Jersey, graduate and MBA degrees from The University of Texas at Austin, an undergraduate degree from the University of Dallas, and a graduate degree from Maurice A.
Deane School of Law at Hofstra University (2006).
Mr. Rosellini is also the founder of Texas Onsite Dental.
Aktive Positionen von William Michael Rosellini
| Unternehmen | Position | Beginn |
|---|---|---|
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Founder | 01.06.2019 |
Ehemalige bekannte Positionen von William Michael Rosellini
| Unternehmen | Position | Ende |
|---|---|---|
| NEXEON MEDSYSTEMS INC | Chief Executive Officer | 22.10.2020 |
Rosellini Scientific LLC
 Rosellini Scientific LLC Medical SpecialtiesHealth Technology Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini. | Founder | 01.12.2016 |
| MARATHON DIGITAL HOLDINGS, INC. | Director/Board Member | 01.09.2016 |
| The University of Texas at Dallas | Corporate Officer/Principal | 01.08.2015 |
Sarif Biomedical LLC
 Sarif Biomedical LLC Medical SpecialtiesHealth Technology Part of Marathon Digital Holdings, Inc., Sarif Biomedical LLC is a private company that manufactures surgery related equipment. The company is based in Tool, TX. Sarif Biomedical was acquired by Marathon Digital Holdings, Inc. on May 02, 2014 for $0.55 million. | Chief Executive Officer | 01.08.2014 |
Ausbildung von William Michael Rosellini
| University of Southern California | Graduate Degree |
| Rutgers State University of New Jersey | Graduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| University of Dallas | Undergraduate Degree |
| Maurice A. Deane School of Law at Hofstra University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MARATHON DIGITAL HOLDINGS, INC. | Technology Services |
| NEXEON MEDSYSTEMS INC | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Nuviant Medical, Inc.
 Nuviant Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Nuviant Medical, Inc. provides janitorial services. The firm offers commercial and healthcare cleaning services. The company was founded in 1997 and is headquartered in Dallas, TX. | Commercial Services |
MicroTransponder, Inc.
 MicroTransponder, Inc. Medical SpecialtiesHealth Technology MicroTransponder, Inc. develops wireless neurostimulation system for the treatment of chronic pain and other neurological indications. It is a medical device company spun out from the University of Texas at Dallas. The firm has an team of neuroengineers collaborating with academics to develop wireless solutions to treat neurological diseases. The company was founded by Lawrence James Cauller, Thomas James Curnes II and William Michael Rosellini in June 2009 and is headquartered in Austin, TX. | Health Technology |
| Texas Onsite Dental | |
| Lexington Technology Group, Inc. | Finance |
Rosellini Scientific LLC
Rosellini Scientific LLC Medical SpecialtiesHealth Technology Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini. | Health Technology |
Sarif Biomedical LLC
Sarif Biomedical LLC Medical SpecialtiesHealth Technology Part of Marathon Digital Holdings, Inc., Sarif Biomedical LLC is a private company that manufactures surgery related equipment. The company is based in Tool, TX. Sarif Biomedical was acquired by Marathon Digital Holdings, Inc. on May 02, 2014 for $0.55 million. | Health Technology |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Health Technology |
